Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Green

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Genetics|June 16, 2020
Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting ChallengesSteven D Green, Heiko Konig
Blood|October 2, 2024
How I treat secondary acute myeloid leukemiaSteven D Green, Eunice S Wang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2022
TP53 or Not TP53: That Is the QuestionSteven D Green, Joshua F Zeidner
Leukemia Research Reports|June 21, 2024
Acute leukemia with <i>KMT2A</i> rearrangement: A master of disguiseSawyer J Bawek, Eunice S Wang, Steven D Green
BMJ Case Reports|February 6, 2021
Clinical conundrum: managing iron overload after renal transplantationBinayak Upadhyay, Steven D Green, Nabin Khanal, et al.
Journal of Cellular and Molecular Medicine|July 2, 2021
Engineering Tools for Regulating Hypoxia in Tumour ModelsMin Hee Kim, Steven D Green, Chien-Chi Lin, et al.
Current Hematologic Malignancy Reports|February 20, 2021
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment OptionsDaniel R Richardson, Steven D Green, Matthew C Foster, et al.
Expert Review of Anti-Infective Therapy|September 7, 2020
Management of fever and neutropenia in the adult patient with acute myeloid leukemiaAndrew M Peseski, Mitchell McClean, Steven D Green, et al.
Expert Review of Hematology|May 27, 2021
CD123-targeted therapy in acute myeloid leukemiaManuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F Zeidner, et al.
Blood Cancer Journal|September 4, 2023
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemiaHassan Awada, Mina Abdelmalek, Tara Cronin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Genetics|June 16, 2020
Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting ChallengesSteven D Green, Heiko Konig
Blood|October 2, 2024
How I treat secondary acute myeloid leukemiaSteven D Green, Eunice S Wang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2022
TP53 or Not TP53: That Is the QuestionSteven D Green, Joshua F Zeidner
Leukemia Research Reports|June 21, 2024
Acute leukemia with <i>KMT2A</i> rearrangement: A master of disguiseSawyer J Bawek, Eunice S Wang, Steven D Green
BMJ Case Reports|February 6, 2021
Clinical conundrum: managing iron overload after renal transplantationBinayak Upadhyay, Steven D Green, Nabin Khanal, et al.
Journal of Cellular and Molecular Medicine|July 2, 2021
Engineering Tools for Regulating Hypoxia in Tumour ModelsMin Hee Kim, Steven D Green, Chien-Chi Lin, et al.
Current Hematologic Malignancy Reports|February 20, 2021
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment OptionsDaniel R Richardson, Steven D Green, Matthew C Foster, et al.
Expert Review of Anti-Infective Therapy|September 7, 2020
Management of fever and neutropenia in the adult patient with acute myeloid leukemiaAndrew M Peseski, Mitchell McClean, Steven D Green, et al.
Expert Review of Hematology|May 27, 2021
CD123-targeted therapy in acute myeloid leukemiaManuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F Zeidner, et al.
Blood Cancer Journal|September 4, 2023
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemiaHassan Awada, Mina Abdelmalek, Tara Cronin, et al.
Pageof 2